On July 29, Jiuzhou PharmaceuticalThe announcement stated that it had received the " Chemical Raw Materials" issued by the State Food and Drug Administration regarding dapagliflozin.The company has received a "Notice of Approval of the Drug Marketing Application" (Notification No. 2025YS00631), confirming that the dapagliflozin API meets the relevant drug registration requirements and formally approved its registration. This will further enrich the company's product portfolio and enhance its market competitiveness.

Dapagliflozin tablets are an important hypoglycemic drug, primarily used to treat adult patients with type 2 diabetes, and are widely used clinically. The announcement indicates that in the first half of 2024, domestic sales of dapagliflozin tablets reached approximately 3.338 billion yuan. As of the date of the announcement, Jiuzhou Pharmaceutical has invested approximately 5.05 million yuan in the research and development of dapagliflozin. Currently, major domestic manufacturers of dapagliflozin APIs include CSPC Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. and Jiangsu Huiju Pharmaceutical Co., Ltd.

Jiuzhou Pharmaceutical was founded in 1998 and is headquartered in Taizhou, Zhejiang .A custom research and development and manufacturing (CDMO) company dedicated to providing one-stop CDMO services to global pharmaceutical companies, biotechnology companies, and research institutions, including small molecule chemical drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs.

Source：https://finance.eastmoney.com/a/202507303471597075.html